Matches in Wikidata for { <http://www.wikidata.org/entity/Q86169515> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q86169515 description "clinical trial" @default.
- Q86169515 description "ensayu clínicu" @default.
- Q86169515 description "klinisch onderzoek" @default.
- Q86169515 description "клінічне випробування" @default.
- Q86169515 name "Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder (2012-04-30)" @default.
- Q86169515 name "Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder (2012-04-30)" @default.
- Q86169515 type Item @default.
- Q86169515 label "Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder (2012-04-30)" @default.
- Q86169515 label "Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder (2012-04-30)" @default.
- Q86169515 prefLabel "Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder (2012-04-30)" @default.
- Q86169515 prefLabel "Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder (2012-04-30)" @default.
- Q86169515 P1132 Q86169515-49CDF28A-26FE-4728-AF64-CA1CDC69BF05 @default.
- Q86169515 P1476 Q86169515-ADF739BD-BAD3-4FE6-9D28-7F8360B39959 @default.
- Q86169515 P17 Q86169515-0347E8C5-22B4-4EFD-B577-029B4F769712 @default.
- Q86169515 P17 Q86169515-07413D4B-AC86-439E-9888-94BBA604C721 @default.
- Q86169515 P17 Q86169515-3584F00C-F198-4CD6-9727-72B91FC55F2D @default.
- Q86169515 P17 Q86169515-3A39D1C9-D9E7-4278-9B52-B3F6BCB0FA42 @default.
- Q86169515 P17 Q86169515-A735CF65-87F8-4B17-9EBC-33F51FA437AD @default.
- Q86169515 P2899 Q86169515-1E8CF740-C6CD-45D0-913D-C3413360EB79 @default.
- Q86169515 P3098 Q86169515-6FE953AA-5753-4D76-8754-7D128CC66818 @default.
- Q86169515 P31 Q86169515-8D08698C-47F7-4646-A2E5-1DBF0F074E4B @default.
- Q86169515 P4135 Q86169515-D2462E18-36DF-4613-8235-E9D2382C5A27 @default.
- Q86169515 P4844 Q86169515-1B9D71CB-7040-4B54-A6E9-890B10681A27 @default.
- Q86169515 P4844 Q86169515-BA4755D3-C536-4A9E-9586-2CA9EB789E14 @default.
- Q86169515 P580 Q86169515-D6EE1ADA-9090-4DC4-9520-8D5A2592F1CD @default.
- Q86169515 P582 Q86169515-7EDD2116-84A3-48E5-965C-26D89C1BFB83 @default.
- Q86169515 P6099 Q86169515-003A2279-67E9-4B62-8705-D9FE1AD98E7A @default.
- Q86169515 P8363 Q86169515-51B77329-7645-4A99-BD32-44A59606D02B @default.
- Q86169515 P1132 "+549" @default.
- Q86169515 P1476 "A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)" @default.
- Q86169515 P17 Q16 @default.
- Q86169515 P17 Q183 @default.
- Q86169515 P17 Q28 @default.
- Q86169515 P17 Q30 @default.
- Q86169515 P17 Q34 @default.
- Q86169515 P2899 "+13" @default.
- Q86169515 P3098 "NCT01552902" @default.
- Q86169515 P31 Q30612 @default.
- Q86169515 P4135 "+17" @default.
- Q86169515 P4844 Q27289243 @default.
- Q86169515 P4844 Q422112 @default.
- Q86169515 P580 "2012-04-01T00:00:00Z" @default.
- Q86169515 P582 "2014-05-01T00:00:00Z" @default.
- Q86169515 P6099 Q42825046 @default.
- Q86169515 P8363 Q78089383 @default.